Subscribe

Iconovo AB (publ) (ICO.ST)

SEK1.05 -0.03 (-2.78%)
SE STO Healthcare Medical - Devices
Address Medicon Village 223 81
Lund, SE
CEO Anders Mansson
Website iconovo.se
IPO 2018-04-06
ISIN SE0010868943

Explore sections of this company profile

Description

Based in Lund, Sweden, Iconovo AB (publ) focuses on the creation and licensing of advanced inhalation delivery systems. Their product portfolio encompasses a variety of dry powder inhalers, such as the versatile multi-dose ICOres, the capsule-driven ICOcap, the single-use disposable ICOone, and the pre-metered ICOpre. Beyond these standard devices, the company also designs custom inhalation solutions, primarily catering to generic pharmaceutical firms. Iconovo is involved in significant collaborative ventures, including a project with Immune System Regulation AB to develop an inhaled COVID-19 vaccine using their ICOone inhaler, and a partnership with Respiratorius AB (publ) to formulate an inhalation treatment for COPD. The company was established in 2013.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
SEK1.05 -0.03 (-2.78%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
69.7K
Beta
0.39
Float Shares
50.18M
Free Float %
96.5%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.42% +8.64% -2.05% +3.91% -5.91% +6.70% +1.27% -96.49% -98.26% -96.68% -96.68%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.05
DCF (Unlevered) 0.04 -95.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2026-05 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
-0.06
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Devices: +11.2%
    -62.3% Q1'26: +44.5% (vs Q1'25)
  • ✗
    EPS growth Medical - Devices: +28.5%
    +55.6% ★ Q1'26: +81.1% (vs Q1'25)
  • ✗
    FCF margin FCF growth · Medical - Devices: +30.9%
    -69.1% Q1'26: -812.1% (vs Q1'25)
  • ✗
    EBIT margin Medical - Devices: +6.2%
    -3,959.6% Q1'26: -1,210.5% (vs Q1'25)
  • ✗
    ROIC Medical - Devices: +3.3%
    -37.6% Q1'26: -28.6% (vs Q1'25)
  • ✗
    Share dilution Medical - Devices: 0.0%
    +137.6% Q1'26: +264.5% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    -0.15× Q1'26: -0.23× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.38) × ERP
WACC = 90% × Ke + 10% × Kd (9.0%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 0.04 Current price: 1.05
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana. 		Dec 2027
1 Rev. Ana.
1 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
11.91M
est: 12.00M (-0.8%)
11.74M
est: 12.00M (-2.2%)
17.79M
est: 20.40M (-12.8%)
15.41M
est: 17.30M (-10.9%)
17.12M
est: 17.00M (+0.7%)
7.08M
est: 27.13M (-73.9%)
2.93M
est: 33.90M (-91.3%)
1.11M
est: 9.55M (-88.4%)
29.00M
29.00M – 29.00M
+203.7% YoY
2.00M
2.00M – 2.00M
-93.1% YoY
37.00M
37.00M – 37.00M
+1,750.0% YoY
EBITDA
-3.75M
est: -11.84M (+68.4%)
-11.08M
est: -11.84M (+6.5%)
-16.62M
est: -20.13M (+17.4%)
-24.90M
est: -17.07M (-45.9%)
-38.73M
est: -16.78M (-130.9%)
-35.29M
est: -27.13M (-30.1%)
-29.83M
est: -33.90M (+12.0%)
-34.05M
est: -9.55M (-256.6%)
-29.00M
-29.00M – -29.00M
-203.7% YoY
-2.00M
-2.00M – -2.00M
+93.1% YoY
-37.00M
-37.00M – -37.00M
-1,750.0% YoY
EBIT
-4.29M
est: -11.91M (+63.9%)
-11.39M
est: -11.91M (+4.4%)
-17.13M
est: -20.25M (+15.4%)
-26.16M
est: -17.17M (-52.3%)
-47.86M
est: -16.87M (-183.6%)
-45.38M
est: -27.13M (-67.3%)
-40.59M
est: -33.90M (-19.7%)
-43.75M
est: -9.55M (-358.1%)
-29.00M
-29.00M – -29.00M
-203.7% YoY
-2.00M
-2.00M – -2.00M
+93.1% YoY
-37.00M
-37.00M – -37.00M
-1,750.0% YoY
Net Income
-4.29M
est: -9.13M (+53.0%)
-11.01M
est: -21.16M (+48.0%)
-17.13M
est: -31.89M (+46.3%)
-26.16M
est: -43.05M (+39.2%)
-50.31M
est: -78.85M (+36.2%)
-45.89M
est: -114.76M (+60.0%)
-41.14M
est: -65.44M (+37.1%)
-43.36M
est: -25.49M (-70.1%)
-15.98M
-15.98M – -15.98M
+37.3% YoY
-13.31M
-13.31M – -13.31M
+16.7% YoY
-13.31M
-13.31M – -13.31M
+0.0% YoY
SGA
4.10M
est: 73.41M (-94.4%)
6.74M
est: 73.41M (-90.8%)
9.46M
est: 124.79M (-92.4%)
11.55M
est: 105.83M (-89.1%)
58.92M
est: 103.99M (-43.3%)
63.35M
est: 163.08M (-61.2%)
49.62M
est: 203.77M (-75.6%)
—
est: 57.40M (-100.0%)
174.32M
174.32M – 174.32M
+203.7% YoY
12.02M
12.02M – 12.02M
-93.1% YoY
222.41M
222.41M – 222.41M
+1,750.0% YoY
EPS
-0.66
est: -0.57 (-15.7%)
-1.62
est: -1.32 (-22.5%)
-2.20
est: -1.99 (-10.4%)
-3.15
est: -2.69 (-17.1%)
-5.69
est: -4.93 (-15.5%)
-4.39
est: -3.02 (-45.5%)
-2.57
est: -1.72 (-49.4%)
-1.14
est: -0.67 (-70.1%)
-0.42
-0.42 – -0.42
+37.3% YoY
-0.35
-0.35 – -0.35
+16.7% YoY
-0.35
-0.35 – -0.35
+0.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-28 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-27 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-26 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-25 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-22 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-21 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-20 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-19 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-18 C 2/5 1/5 1/5 1/5 3/5 1/5 4/5
2026-05-15 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-13 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-12 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-11 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-08 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-07 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-05 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-05-04 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-04-30 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-04-29 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-04-28 C+ 2/5 1/5 1/5 1/5 3/5 1/5 5/5
2026-04-27 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-24 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-23 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-22 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-21 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-20 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-17 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-04-16 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-36.86M
OE per share TTM
-1.02
Owner's Yield
-39.70%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
95.6%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
-16.8K
Shares Outstanding
52.00M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Anders Mansson Chief Executive Officer — male
Carl Forslund Head of Industrial Design — male
Henrik Damkjaer Simonsen Chief Financial Officer — male
Lotta Askerlund HR Manager — female
Madeleine Hiller Business Controller — —
Maria Ekblad Head of Generics Development — female
Mikael Arinder Head of Science & Technology — —
Orest Lastow Co-Founder, Senior Scientific Advisor & Director — —
Vesna Åkerberg Head of Novel & Reformulation Development — female
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Devices